FridayOct 30, 2020 3:00 pm

Study Finds Microdosing on Psychedelics Provides More Benefits Than Disadvantages

According to new research published in the “Journal of Psychopharmacology,” individuals who take microdoses of psychedelic drugs report improvements in creativity and mood. Rotem Petranker, the study author, and his colleagues observed a growth in public interest with regard to consuming microdoses of psilocybin or LSD. This purportedly helps enhance emotional or cognitive functioning. However, this has not been proven because of insufficient research. Petranker, who is the associate director of the University of Toronto’s Psychedelic Studies Research Program explains that any individual who is interested in mapping out consciousness should consider psychedelics as a useful perspective. He adds that…

Continue Reading

ThursdayOct 29, 2020 3:30 pm

Study Suggests Psychedelics May Encourage Connectedness, Reduce Narcissism

In a new study published in “Psychopharmacology,”, researchers argue that feelings of awe elicited from psychedelic drugs may influence narcissistic personality traits positively. The study discovered that psychedelic experiences that evoke feelings of awe were connected to increased feelings of empathy and connectedness, which are linked to reduced levels of exploitative-entitled narcissism. Because prior research had demonstrated that psychedelic substances could improve mental well-being and intensify feelings of social connectedness, the researchers of this study chose to instead focus on finding out whether the effects from these substances had an impact on narcissism. The study authors, Ruairi Patterson, a University…

Continue Reading

WednesdayOct 28, 2020 3:45 pm

Voters in Key Jurisdictions Now Have Chance to Vote on Psychedelics

As psychedelics go mainstream and more states look into decriminalization, it appears fairly certain that these substances will be legalized in the near future. And with the many benefits they provide therapeutically, we may see an increase in the number of alternative psychedelic treatments for various ailments over the next few years. The FDA has granted both psilocybin and MDMA breakthrough therapy status, which will help expedite their legalization for use as mental health medications for mental disorders. As a result of this expectation, concerns are being raised about how psychedelics will become legal. With organizations such as Decriminalize Nature…

Continue Reading

TuesdayOct 27, 2020 1:39 pm

Legal, Regulatory Aspects Psychedelics Companies Should Consider Before Going Public

In the past few months, many of the stocks that were the most actively traded on the Canadian Securities Exchange were shares of firms involved in the psychedelics industry. Firms operating in the psychedelics industry have also listed on the NEO Exchange and TSX Venture Exchange in Canada. Additionally, other firms in the sector are currently raising capital to help develop their businesses and are planning on “going public” in Canada. A common misconception is that all these companies raising capital from the investment community and listing on stock exchanges are psychedelics companies. It should be noted that the firms…

Continue Reading

MondayOct 26, 2020 11:43 am

Lessons from Psilocybin and Ketamine

As you may have noticed, psychedelics are becoming mainstream, with media interest and research into these mind-altering substances steadily growing. However, the research on psychedelics remains problematic given the regulatory and legal barriers imposed on studying these drugs in a laboratory setting. In recent years, innovative research centers such as MAPS (Multidisciplinary Association for Psychedelic Studies), the Imperial College London and Johns Hopkins have studied these psychedelics in order to discover potential treatments for psychiatric disorders In addition to this, not-for-profit organizations such as the Usona Institute have invested heavily in the future of psychedelics. Furthermore, Compass Pathways, a private…

Continue Reading

MondayOct 26, 2020 10:13 am

Medicinal Mushrooms Booming, Pure Extract Technologies Inc. First-Mover Strategy Catalyzing Growth

Research indicates that functional and medicinal mushrooms offer range of physical and mental benefits Pure Extracts’ milestone-based strategy catalyzing Company growth Strategy includes license procurement, production, marketing of in-house and white label products Mainstream science is now catching up with what traditional medicine has known for years — that functional and medicinal mushrooms can help treat disease, improve mental cognition and fire up digestion. Pure Extract Technologies Inc., a soon-to-be public, plant-based Canadian extraction company, is on track to position itself as an industry leader through a strategy based on three growth-focused milestones that include the application to Health Canada…

Continue Reading

FridayOct 23, 2020 3:27 pm

Ayahuasca, the Experienced Trauma Therapist

In whatever form it is administered, ayahuasca, a psychoactive brew or tea, has the extensive capacity to illuminate issues underlying addiction, anxiety and also depression. most commonly derived from Banisteriopsis caapi, a vine containing monoamine oxidase inhibitors, and the leaves of Psychotria viridis, ayahuasca often reveals the unprocessed drama that is at the root of these issues. The awareness ayahuasca brings allows deep healing to occur. Neurological research has shown that trauma affects the emotional brain more than it does the rational brain. While research has not definitively identified the neurophysiological mechanisms through which eye movement desensitization and reprocessing (EMDR) and…

Continue Reading

FridayOct 23, 2020 1:30 pm

Pure Extract Technologies Inc.’s Three-Pillar Business Model Points Company Toward Success

‘Harvard Business Review’ cites importance of a good business model, specifies key questions it should answer. Pure Extracts’ business model founded on three pillars: extraction services, formulation & white-labeling, and development of its in-house ‘Pure Pulls’ branded cannabis and functional mushroom products. Company’s business model is multi-faceted, comprehensive and allows for future growth. A strong business model is essential to every successful organization, whether it’s a new venture or an established player, touts a “Harvard Business Review” article titled “Why Business Models Matter.” Pure Extracts Technologies Corp., a plant-based extraction company with a new vertical in functional mushrooms, recognizes the…

Continue Reading

ThursdayOct 22, 2020 10:22 am

How Psychedelics Promote Neuron Growth

As psychedelic research continues to gain traction, many wonder how these mind-altering substances work in the brain and how they help reduce symptoms of various mental disorders and provide long-lasting improvements. While scientists seem to have various well-founded hypotheses, there still isn’t enough experimental evidence available on psychedelics to provide adequate answers about how these substances are responsible for therapeutic response. However, new findings published in “Cell Reports,” a prominent scientific journal, indicate that ibogaine and classic psychedelics, such as LSD, DMT and psilocybin, as well as amphetamine analogs, i.e., DOI and MDMA, all converge at mTor (in the brain)…

Continue Reading

ThursdayOct 22, 2020 9:57 am

Cybin Corp. Appoints New CEO with Impressive Health-Care Expertise

Cybin appoints health-care expert Doug Drysdale as new CEO. Company confident that his extensive health-care sector background, international company management skills will strengthen Cybin partnerships. New CEO says business model, talented management team positions company to examine new psychedelic-based therapies, delivery systems. Cybin Corp.,a life sciences company advancing psychedelic pharmaceuticals, recently announced the appointment of Doug Drysdale as its CEO (https://ibn.fm/vOTXM). Drysdale brings more than three decades of experience in the health-care sector and will continue to grow its IP portfolio. “With his myriad business accomplishments, Doug is the ideal leader for Cybin,” said Cybin co-founder and COO Paul Glavine. “We…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050